ArticleCancer science2006
Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
Article in Cancer science, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Evaluation of respiratory toxicity and peritoneal mesothelioma induced by heat-treated and milled amosite following intratracheal and intraperitoneal injection in rats.Industrial health · 2026Article
- Radioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Mesothelioma carcinogenesis of chrysotile and forsterite compared and validated by intraperitoneal injection in rat.Industrial health · 2025Article
- Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.Juntendo Iji zasshi = Juntendo medical journal · 2023Article
- Article
- In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.Cancer science · 2019Review
- Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.Translational lung cancer research · 2017Review
- Environmental carcinogenesis - 100th anniversary of creating cancer.Cancer science · 2015Review
- Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.Cancer medicine · 2014Article
- Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.Molecular & cellular proteomics : MCP · 2014Article
- Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.Molecular and clinical oncology · 2014Article
- ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.Oncology reports · 2014Article
- Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.PloS one · 2014Article
- Folate receptor alpha, mesothelin and megakaryocyte potentiating factor as potential serum markers of chronic kidney disease.Biomarker insights · 2014Article
- C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma.Journal of gastroenterology · 2014Article
- The continual search for ideal biomarkers for mesothelioma: the hurdles.Journal of thoracic disease · 2013Article
- Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.Journal of ovarian research · 2013Article
- The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.Journal of thoracic disease · 2013Article
- Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.Disease markers · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have developed a novel enzyme-linked immunosorbent assay (ELISA) system for the detection of N-ERC/mesothelin in the serum of mesothelioma patients and have begun to examine its clinical usefulness. N-ERC/mesothelin is a 31-kDa protein that forms the N-terminal fragment of the full-length 71-kDa ERC/mesothelin protein, and is physiologically secreted into the blood of mesothelioma patients where it can be detected using our sandwich ELISA containing two antibodies (rabbit polyclonal anti-ERC/mesothelin antibody-282 and mouse monoclonal antibody 7E7). Our ELISA system has thus far detected much higher serum levels of N-ERC/mesothelin in mesothelioma patients than in healthy controls or patients with other lung or pleural diseases. In conclusion, N-ERC/mesothelin is a promising candidate tumor marker for mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.